* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Gene Section PA2G4 (proliferation associated 2G4, 38kDa) -
Survey
Document related concepts
Transcript
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Gene Section Review PA2G4 (proliferation-associated 2G4, 38kDa) Anne Hamburger, Arundhati Ghosh, Smita Awasthi University of Maryland School of Medicine, Department of Pathology and University of Maryland Greenebaum Cancer Center, Baltimore, USA (AH, AG, SA) Published in Atlas Database: September 2011 Online updated version : http://AtlasGeneticsOncology.org/Genes/PA2G4ID41628ch12q13.html DOI: 10.4267/2042/46944 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology Identity DNA/RNA Other names: EBP1, HG4-1, ITAF45, p38-2G4 HGNC (Hugo): PA2G4 Location: 12q13.2 Note PA2G4 encodes a cell-cycle regulated protein capable of interacting with DNA, RNA and protein. The gene was isolated as a DNA binding protein (p38-2g4) (Radomski and Jost, 1995) and also as an ErbB3interacting protein (EBP1) (Yoo et al., 2000). Two different isoforms of EBP1 play a role in cell survival, cell cycle arrest and differentiation. The long form may have an oncogenic function when overexpressed, and the short form acts as a tumor suppressor (Liu et al., 2006). EPB1 also functions as a transcriptional repressor of E2F1-regulated genes (Zhang et al., 2004) and the androgen receptor (AR) (Zhang et al., 2005) through its interactions with histone deacetylases and Sin3A. Description The PA2G4 gene contains 13 exons. The sizes of the exons 1-13 are 88, 128, 105, 69, 92, 63, 78, 78, 133, 94, 127, 53 and 65 bp (to the stop codon). Exon 1 contains the translation initiation ATG. Exon 13 contains the stop codon. Transcription The human PA2G4 promoter contains several putative transcription factor binding sites. The major transcript length is 2643 nt. Two proteins are translated due to alternative splicing (Liu et al., 2006). An alternatively spliced version missing 29 NT between the first and third ATGs has been observed. The PA2G4 promoter contains two tandem DNA elements that bind E2F1. E2F1 increases endogenous EBP1 mRNA levels in cancer cells, but decreases EBP1 mRNA abundance in non transformed cells (Judah et al., 2010). Pseudogene Six pseudogenes, located on chromosomes 3, 6, 9, 18, 20 and X, have been identified. The alignment of PA2G4 mRNA to its genomic sequence. Atlas Genet Cytogenet Oncol Haematol. 2012; 16(2) 131 PA2G4 (proliferation-associated 2G4, 38kDa) Hamburger A, et al. The linear schematic of EBP1. Functional domains, including Nucleolar Localization Signal (NuLS), σ70 RNA binding region (σ70), amphipathic helical domain (AHD), LXXLL nuclear receptor binding motif (LX) and demonstrated in vivo phosphorylation sites (*). Localisation Protein Description p38-2G4 was initially isolated as a DNA binding protein from mouse Ehrlich ascites cells (Radomski and Jost, 1995). The MW of this protein is predicted to be 38058 D, consisting of 340 amino acids. The human orthologue EBP1 was later identified as an ErbB3 binding protein of the same MW as the mouse protein (Yoo et al., 2000). This form migrates at approximately 42 kD in SDS-PAGE gels. Later, a larger 394 amino acid form (predicted MW 43787 D, migrating at 48 kD) was observed in mammalian cells (Xia et al., 2001). The two forms have been demonstrated to be the result of alternative splicing (Liu et al., 2006) or usage of alternative translation initiation sites (Xia et al., 2001). Amino acids 1-48 are required for nucleolar localization and the C terminal domain (aa 364-394) is required for interactions with nucleic acids (Moonie et al., 2007) and protein (Zhang et al., 2002). EBP1 is post translationally modified at several phosphorylation sites (Ser 360 (Ahn et al., 2006), Ser 363 (Akinmade et al., 2007) and Thr 261 (Akinmade et al., 2008)) in vivo. The protein stability of the short form is regulated by ubiquitination (Liu et al., 2009). The short form is also sumoylated by the TLF/FUS E3 ligase and this sumoylation is required for the antiproliferative effects of EBP1 (Oh et al., 2010). The crystal structure of both murine (Monie et al., 2007) and human (Kowalinski et al., 2007) EBP1 has been solved. There is a core domain that is homologous to methionine aminopeptidases, although no enzymatic activity has been reported. The C terminal domain containing a Lys-rich nuclear hormone receptor binding motif (LKALL) was reported to mediate RNA binding (Monie et al., 2007). Expression EBP1 has been found to be ubiquitously expressed with high expression levels in skeletal muscle (Yoo et al., 2000). Atlas Genet Cytogenet Oncol Haematol. 2012; 16(2) 132 Under logarithmically growing conditions in cell culture, EBP1 localizes to the nucleolus and the cytoplasm (Xia et al., 2001; Squatrito et al., 2004). Upon stimulation with the ErbB3 ligand heregulin, the short form of EBP1 is recruited to the nucleus in AU565 breast cancer cells (Yoo et al., 2000). Sumoylation is required for nuclear translocation (Oh et al., 2010). In primary normal epithelial cells, EBP1 is confined to the cytoplasm (Zhang et al., 2008b). Function EBP1 was initially isolated as a cell cycle-regulated DNA binding protein (Radomski and Jost, 1995) and has been shown to induce cell cycle arrest in the G2/M phase of the cell cycle (Zhang et al., 2005). EBP1 acts as a corepressor for several proliferation-associated genes including Cyclin D1, E2F1 (Zhang and Hamburger, 2004) and the androgen receptor (Zhang et al., 2005). EBP1 inhibits transcription of these genes by recruiting HDAC2 via Sin3A to the E2F1 and ARregulated promoters (Zhang et al., 2005). EBP1 interacts with RB1 and the interaction is enhanced upon EBP1 dephosphorylation (Xia et al., 2001). EBP1 was isolated as an ErbB3 binding protein using a yeast-two hybrid screen (Yoo et al., 2000). The interactions of EBP1 with ErbB3 is disrupted by the ErbB3 ligand heregulin, leading to EBP1 nuclear translocation. This leads to the eventual inhibition of heregulin-stimulated proliferation, presumably due to the repression of proliferation associated genes (Zhang et al., 2008a). EBP1 also binds RNA and associates with 28S, 18S and 5.8S mature rRNAs, several rRNA precursors and probably U3 small nucleolar RNA. It has been implicated in the regulation of intermediate and late steps of rRNA processing (Squatrito et al., 2004; Squatrito et al., 2006). EBP1 also mediates capindependent translation of specific viral IRES (internal ribosome entry site) (Pilipenko et al., 2000). EBP1 PA2G4 (proliferation-associated 2G4, 38kDa) Hamburger A, et al. regulates translation of AR mRNA (Zhou et al., 2010). EBP1 has also been implicated in protein stability via its interaction with the proteasome. Overexpression of EBP1 results in decreased stability of ErbB2 protein in breast cancer cells via a proteasome-mediated pathway (Lu et al., 2011). The long form of EBP1 binds to the p53 E3 ligase HDM2, enhancing HDM2-p53 interactions and promoting p53 degradation (Kim et al., 2011). The long (p48) and short (p42) forms of EBP1 have opposing biological effects, with the longer form inducing cell survival and the shorter form inhibiting cell growth (Liu et al., 2006). The long form binds HDM2, promoting degradation of p53 (Kim et al., 2010). Homology Similar (30% identity) to the 42 kDA DNA binding protein SF00553 in S. pombe yeast (Yamada et al., 1994) and StEBP1 in potato (Horvath et al., 2006). The orthologue in potatoes (StEBP1) has 69% sequence similarity to human EBP1 and can inhibit growth of human breast cancer cell lines and E2F1 expression in these cells. References Yamada H, Mori H, Momoi H, Nakagawa Y, Ueguchi C, Mizuno T. A fission yeast gene encoding a protein that preferentially associates with curved DNA. Yeast. 1994 Jul;10(7):883-94 Radomski N, Jost E. Molecular cloning of a murine cDNA encoding a novel protein, p38-2G4, which varies with the cell cycle. Exp Cell Res. 1995 Oct;220(2):434-45 Pilipenko EV, Pestova TV, Kolupaeva VG, Khitrina EV, Poperechnaya AN, Agol VI, Hellen CU. A cell cycle-dependent protein serves as a template-specific translation initiation factor. Genes Dev. 2000 Aug 15;14(16):2028-45 Yoo JY, Wang XW, Rishi AK, Lessor T, Xia XM, Gustafson TA, Hamburger AW. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer. 2000 Feb;82(3):683-90 Xia X, Cheng A, Lessor T, Zhang Y, Hamburger AW. Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol. 2001 May;187(2):20917 Squatrito M, Mancino M, Donzelli M, Areces LB, Draetta GF. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene. 2004 May 27;23(25):4454-65 Zhang Y, Hamburger AW. Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription. J Biol Chem. 2004 Jun 18;279(25):26126-33 Mutations Germinal Zhang Y, Akinmade D, Hamburger AW. The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and ARmediated transcription. Nucleic Acids Res. 2005;33(18):602433 No mutations in the PA2G4 gene have been reported. Somatic None reported. Ahn JY, Liu X, Liu Z, Pereira L, Cheng D, Peng J, Wade PA, Hamburger AW, Ye K. Nuclear Akt associates with PKCphosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J. 2006 May 17;25(10):2083-95 Implicated in Prostate cancer Prognosis Decreased expression of EBP1 is associated with higher tumor grade and metastasis in prostate cancer (Zhang et al., 2008b). However, another study indicated EBP1 expression increased with disease progression (Gannon et al., 2008). Horváth BM, Magyar Z, Zhang Y, Hamburger AW, Bakó L, Visser RG, Bachem CW, Bögre L. EBP1 regulates organ size through cell growth and proliferation in plants. EMBO J. 2006 Oct 18;25(20):4909-20 Breast cancer Ou K, Kesuma D, Ganesan K, Yu K, Soon SY, Lee SY, Goh XP, Hooi M, Chen W, Jikuya H, Ichikawa T, Kuyama H, Matsuo E, Nishimura O, Tan P. Quantitative profiling of drugassociated proteomic alterations by combined 2nitrobenzenesulfenyl chloride (NBS) isotope labeling and 2DE/MS identification. J Proteome Res. 2006 Sep;5(9):2194206 Prognosis Deletion of EBP1 results in tamoxifen resistance in breast cancer (Zhang et al., 2008a). However, patients with a high level of EBP1 protein have a poor clinical outcome (Ou et al., 2006). Glioblastoma Prognosis Glioblastoma patients expressing a high level of p48 EBP1 have a worse prognosis than those expressing lower levels of the protein (Kim et al., 2010; Kwon and Ahn, 2011). Atlas Genet Cytogenet Oncol Haematol. 2012; 16(2) 133 Liu Z, Ahn JY, Liu X, Ye K. Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10917-22 Squatrito M, Mancino M, Sala L, Draetta GF. Ebp1 is a dsRNAbinding protein associated with ribosomes that modulates eIF2alpha phosphorylation. Biochem Biophys Res Commun. 2006 Jun 9;344(3):859-68 Akinmade D, Lee M, Zhang Y, Hamburger AW. Ebp1-mediated inhibition of cell growth requires serine 363 phosphorylation. Int J Oncol. 2007 Oct;31(4):851-8 PA2G4 (proliferation-associated 2G4, 38kDa) Hamburger A, et al. Kowalinski E, Bange G, Bradatsch B, Hurt E, Wild K, Sinning I. The crystal structure of Ebp1 reveals a methionine aminopeptidase fold as binding platform for multiple interactions. FEBS Lett. 2007 Sep 18;581(23):4450-4 Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y, Roberts LO, Matthews S, Goodfellow IG, Curry S. Structural insights into the transcriptional and translational roles of Ebp1. EMBO J. 2007 Sep 5;26(17):3936-44 Akinmade D, Talukder AH, Zhang Y, Luo WM, Kumar R, Hamburger AW. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells. Br J Cancer. 2008 Mar 25;98(6):1132-40 Gannon PO, Koumakpayi IH, Le Page C, Karakiewicz PI, MesMasson AM, Saad F. Ebp1 expression in benign and malignant prostate. Cancer Cell Int. 2008 Nov 24;8:18 Zhang Y, Akinmade D, Hamburger AW. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Lett. 2008a Jul 8;265(2):298-306 Zhang Y, Linn D, Liu Z, Melamed J, Tavora F, Young CY, Burger AM, Hamburger AW. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther. 2008b Oct;7(10):3176-86 Liu Z, Oh SM, Okada M, Liu X, Cheng D, Peng J, Brat DJ, Sun SY, Zhou W, Gu W, Ye K. Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell. 2009 Feb;20(3):757-68 Atlas Genet Cytogenet Oncol Haematol. 2012; 16(2) 134 Judah D, Chang WY, Dagnino L. EBP1 is a novel E2F target gene regulated by transforming growth factor-β. PLoS One. 2010 Nov 10;5(11):e13941 Kim CK, Nguyen TL, Joo KM, Nam DH, Park J, Lee KH, Cho SW, Ahn JY. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 2010 Dec 1;70(23):9730-41 Oh SM, Liu Z, Okada M, Jang SW, Liu X, Chan CB, Luo H, Ye K. Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity. Oncogene. 2010 Feb 18;29(7):1017-30 Zhou H, Mazan-Mamczarz K, Martindale JL, Barker A, Liu Z, Gorospe M, Leedman PJ, Gartenhaus RB, Hamburger AW, Zhang Y. Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res. 2010 Jun;38(11):3619-31 Kwon IS, Ahn JY. P48 Ebp1 acts as a downstream mediator of Trk signaling in neurons, contributing neuronal differentiation. Neurochem Int. 2011 Feb;58(2):215-23 Lu Y, Zhou H, Chen W, Zhang Y, Hamburger AW. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells. Breast Cancer Res Treat. 2011 Feb;126(1):27-36 This article should be referenced as such: Hamburger A, Ghosh A, Awasthi S. PA2G4 (proliferationassociated 2G4, 38kDa). Atlas Genet Cytogenet Oncol Haematol. 2012; 16(2):131-134.